NFKBID

Across TCGA pan-cancer cohorts, NFKBID Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NFKBID data layer compared with 27 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher NFKBID Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NFKBID expression acts as an unfavorable survival marker.

MESO, BRCA, and STAD are the cancer types where NFKBID Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
BRCA	OS	Median	All	0.133	0.578	.008	16	view →
STAD	OS	Median	IV	0.074	0.496	.002	12	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.435	0.787	.021	6	view →
COAD	OS	Median	All	0.209	0.679	.017	4	view →
LUAD	OS	Median	II,III,IV	0.307	0.748	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NFKBID–MESO (OS)

Open the MESO breakdown →